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Sera of 624 blood donors were evaluated to determine seroprevalence of West Nile virus (WNV) antibodies
following the 2003 WNV epidemic in Nebraska. Geographic factors contributing to differences in WNV
seropositivity were evaluated. The overall prevalence of WNV in Nebraska was higher than reported previously
in other U.S. locations (9.5% WNV immunoglobulin G seroprevalence rate), with the highest prevalence
identified in the western part of the state (19.7%), followed by the central (13.8%) and the eastern (4.2%) parts.
Regions of the state with the highest WNV-positive mosquito rates correlated with the highest human WNV
seroprevalence rates. The results showed that both the western and central parts of the state, where mosquito
positivity rates were highest, had significantly higher seroprevalence rates than the eastern region. Additional
studies are needed to determine whether the high prevalence rates in Nebraska will be reflected in other states
and what impact environmental and geographical factors may have on future outbreaks of WNV infection.
West Nile virus (WNV), a member of the Flaviviridae family,
was first identified in the United States as a cause of disease in
New York City (NYC), N.Y., in 1999 (11). WNV activity has
through December 2005 been detected in all 48 continental
states, as reported to the Centers for Disease Control and
Prevention (CDC) through ArboNET (http://www.cdc.gov
/ncidod/dvbid/westnile/surv&control.htm). The virus was first
detected in Nebraska during the 2002 mosquito season (May
through October) with 152 human cases of WNV-caused dis-
ease identified in the state. An epidemic occurred in 2003 with
1,937 cases reported which resulted in 29 deaths (ArboNET
data). Human seroprevalence studies are limited within the
United States, with a survey of New York City residents in
October 1999 demonstrating that 2.6% of healthy individuals
may have been infected with WNV without symptoms or ex-
hibiting only mild symptoms and a study in one county in
Wyoming estimating that 14% of the residents may have been
infected (3, 13, 14). To evaluate seroprevalence on a statewide
basis, this study determined the presence of WNV-specific
antibodies in blood donors following the 2003 WNV epidemic
in Nebraska. The results of testing were compared to data
collected from mosquito surveillance studies by geographic
regions within the state.
MATERIALS AND METHODS
Specimen collection. A 1-day statewide collection (1 July 2004) of 624 sera by
the American Red Cross (Omaha, Nebraska, office) was used as a source of
specimens for the study. Donors had been screened using a questionnaire mod-
ified to exclude donors with a history of possible acute meningitis to include that
caused by WNV. Sera were also tested for infectious agents including WNV
RNA according to standard blood bank protocols (4, 21). Each donor serum was
included only once. All specimens were deidentified and sorted into three geo-
graphical collection regions as defined by the American Red Cross prior to
testing (Fig. 1). These regions were based on county borders. During the screen-
ing process, approximately 2 ml of excess sera was placed into sterile vials, coded
by collection location, and stored frozen at 70°C until evaluated.
ELISAs. FDA-approved WNV immunoglobulin M (IgM) capture and IgG
enzyme-linked immunosorbent assays (ELISAs) were performed on the speci-
mens. An in-house protocol was used for WNV IgA ELISA. Both the WNV IgM
capture ELISA and the IgG ELISAs (Focus Technologies, Cypress, CA) were
interpreted according to package inserts. These assays were carried out using the
MAGO Plus automated enzyme immunoassay analyzer (Diamedix, Miami, FL).
A manual background subtraction assay, as described in the WNV IgM ELISA
package insert, was performed on all IgM-positive samples. WNV IgA ELISA
was done using the protocols described by Prince and Lape-Nixon (16). Briefly,
the IgA assay was done using a 96-well polystyrene plate (Corning, Corning, NY)
coated with 75 l goat anti-human IgA (KPL, Gaithersburg, MD) at a concen-
tration of 37.5 ng per well in 0.05 M carbonate buffer. This IgA-coated plate
was incubated overnight at 4°C in a humidified chamber. After incubation, the
plate was washed with phosphate-buffered saline containing 0.05% Tween 20
(PBS-T20) (Sigma, St. Louis, MO) using the 96PW microplate washer (Tecan,
Durham, NC). Previously tested patient sera were used as positive and negative
controls. Patient sera and controls were diluted 1:100 in WNV ELISA diluent
(Focus Technologies). Fifty microliters of diluted sample or control was added to
wells of the plate in duplicate. The plate was incubated for 1 h at 37°C in a
humidified chamber followed by five washes in PBS-T20. After the wash step, 50
l of the WNV antigen (Focus Technologies) was added to the patient well and
50 l WNV healthy control antigen (Focus Technologies) was added to the other
well. The plate was subsequently incubated overnight at 4°C in a humidified
chamber. Following the second incubation, the plate was washed five times and
each well was inoculated with 50 l of anti-WNV conjugate (Focus Technolo-
gies) and incubated for 1 h at 37°C. The plate was washed five times in PBS-T20;
each well was inoculated with 75 l of WNV substrate (Focus Technologies), and
the plate was incubated for 10 min in the dark at room temperature. Seventy-five
microliters of WNV stop reagent (Focus Technologies) was added to each well,
and absorbance (A450) was read on the ELx800UV plate reader (Bio-Tek,
Winooski, VT). The data were analyzed as described previously (12).
HAI testing. Hemagglutination inhibition (HAI) assays using WNV- and Saint
Louis encephalitis virus (SLEV)-specific antigens were performed on all IgG
ELISA WNV-positive sera to confirm results (20). Briefly, the sera were treated
with kaolin to remove nonspecific inhibitors (5). Gander red blood cells (G-RBC;
Colorado Serum Company, Denver, Colorado) were prepared by washing the
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cells three times in dextrose-gelatin-Veronal (Cambrex, Walkersville, MD) and
then resuspending them in a pH 6.4 working buffer to a final concentration of 8%
G-RBC (5, 19). A working dilution of 1:24 was made of the G-RBC solution.
WNV and SLEV antigens were obtained from the CDC (Division of Vector-
Borne Infectious Diseases, Fort Collins, Colorado) and rehydrated as directed.
The WNV and SLEV antigens were diluted 1:15 and 1:40, respectively, using a
pH 6.4 working buffer, creating a suspension of 4 to 8 hemagglutination units.
Prior to testing, the sera were diluted 1:40 in 0.4% bovine albumin borate saline
for screening purposes (5, 19). Equal parts (25 l) of the diluted sera, G-RBCs
at a working dilution, and diluted antigens at a pH of 6.4 were placed into a
round-bottomed 96-well microtiter plate (Nalgene Nunc, Rochester, NY) and
incubated overnight at 4°C. Results were interpreted as described by Casals and
Brown (2).
Mosquito testing. Mosquitoes were trapped biweekly using CDC light traps
from June to October 2003 in 20 Nebraska counties (Fig. 1) (15). Trapping of
mosquitoes for 2004 began on 1 June. Female Culex species (C. tarsalis, C.
restuans, C. pipiens, and C. salinarius) were identified (by W.L.K.) and combined
into pools of up to 50 mosquitoes and stored frozen until evaluated. At the time
of testing, the samples were thawed and phosphate-buffered saline, pH 7.4 (at a
ratio of 1.5 ml per 50 mosquitoes), was added to each pool. The pools were
disrupted using the Mixer Mill 300 (QIAGEN Inc., Valencia, CA) at 20 cycles
per second for 4 min. The samples were subsequently centrifuged at 14,000 rpm
for 3 min. A total of 150 l of mosquito supernatant was used for total RNA
extraction on the MagNA Pure LC instrument (Roche, Indianapolis, Indiana)
using the Roche RNA Isolation Kit III with the fresh/frozen protocol and a final
elution volume of 75 l. Reverse transcription-PCR was performed using the
Lightcycler models 1.2 and 2.0 (Roche, Indianapolis, Indiana) with primers
WN9483F (5-CAC CTA CGC CCT AAA CAC TTT CAC C-3) and WN9794R
(5-GGA ACC TGC TGC CAA TCA TAC CAT C-3) (WNV training course
material; CDC Division of Vector-Borne Infectious Diseases, Fort Collins, CO,
February 2001). The Roche RNA master amplification kit utilizes SYBR green
as the fluorescent detector. Two microliters of extracted RNA was combined
with 0.19 l of each primer (0.38 M concentration), 0.5 l of Mn(OAc)2 (2.5
mM concentration), 3.7 l of Roche enzyme, and 3.42 l of water to bring the
final volume to 10 l. The reverse transcription-PCR consisted of an initial
reverse transcription of the RNA at 61°C for 20 min and denaturation of the
cDNA for 95°C for 2 min followed by 40 amplification cycles. Each amplification
cycle consisted of a denaturation step at 95°C for 1 s, an annealing step at 69°C
for 5 s, and an extension step at 72°C for 16 s. The annealing temperature was
adjusted from 69°C to 62°C over the first 12 amplification cycles. Melting tem-
perature analysis was used to identify WNV RNA-positive pools. The melting
curve assay was performed by increasing the temperature from 65°C to 95°C at
0.1°C per second. A mosquito pool known to be positive for WNV was included
in each run for comparison of the melting temperature curve of the unknown
pool with the melting curve of the control pool. Melting curve temperatures of
approximately 85°C were seen with WNV. The minimum infectivity rate (MIR)
was calculated by dividing the number of positive mosquito pools by the number
of mosquitoes tested and expressing this as the number of positive mosquitoes
per 1,000 mosquitoes tested.
Statistical analysis. Ninety-five percent confidence intervals (CIs) were calcu-
lated using SPSS software (SPSS, Inc., Chicago, Illinois). A comparison of prev-
alence rates between geographical regions was made using Fisher’s exact test. A
P value of 0.05 was considered significant.
RESULTS
A total of 624 sera were collected from various regions
within Nebraska (Table 1). In the east region, 15 of 359 sam-
ples were positive for WNV-specific IgG (4.2%; 95% CI, 2.1 to
6.3) and two samples were positive for WNV-specific IgM
(0.6%; 95% CI, 0.0 to 1.3). A significant increase in WNV-
specific IgG positivity was noted for the central region, where
19 of 138 sera were IgG positive (13.8%; 95% CI, 8.0 to 19.6)
compared to the east region (P  0.001). Also, there were
significantly more positive WNV IgM samples in the central
region than in the east region (P  0.01) with a total of six
positive samples (4.3%; 95% CI, 0.9 to 7.8). In comparing the
FIG. 1. Geographic divisions of Nebraska by county. The shaded areas represent the counties where mosquito testing was performed.
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west region to the east region a significant increase in WNV-
specific IgG-positive results was also observed, with 25 of 127
(19.7%; 95% CI, 12.7 to 26.7) donors positive in the west (P 
0.001). However, no statistical difference in the prevalence of
WNV-specific IgM samples was noted in comparing the west to
the east region (P  0.12). Additionally, no statistical differ-
ence was seen in the number of WNV-specific IgG-positive
(P  0.25) or IgM-positive (P 0.50) donors in comparing the
central to the west region.
Overall statewide, 59 sera (9.5%; 95% CI, 7.2 to 11.8) were
positive for WNV-specific IgG and 12 sera (1.9%; 95% CI, 0.8
to 3.0) were positive for WNV-specific IgM. HAI testing con-
firmed that all positive sera contained WNV-specific IgG anti-
bodies. In each donor with a positive WNV-specific IgM, a
corresponding positive result for WNV-specific IgG was noted.
None of the WNV-specific IgM-positive samples were positive
for WNV-specific IgA antibodies (results not shown).
A total of 2,816 Culex species mosquito pools were tested
during the 2003 WNV season in Nebraska (Table 1). The first
positive pool was collected on 19 June 2003, and the last
positive pool was collected on 29 September 2003. WNV RNA
was detected in 75 of 725 pools from the east (10.3%; 95% CI,
8.1 to 12.6), 333 of 928 pools from the west (35.9%; 95% CI,
32.8 to 39.0), and 528 of 1,163 pools from the central (45.4%;
95% CI, 42.5 to 48.3) region of the state. A significant differ-
ence in mosquito positivity was noted in comparing the east or
west to the central region (P  0.001) and in comparing the
east and west regions (P  0.001). Of the 528 positive pools
collected in the central region, 260 (49.2%) were collected
from Dawson County, adjacent to the west region (Fig. 1). The
first WNV-positive mosquito pool for 2004 was collected after
the date of serum collection.
The population of Nebraska according to the 2000 U.S.
census was 1,711,263 people with a concentration of people in
the east region of the state (1,234,018 or 72.1% of the popu-
lation) (Table 2). The population in the central section of the
state was 304,884 (17.8% of total) and in the west was 172,361
(10.1% of total). The overall population density of Nebraska
averaged 22.3 people per square mile. The population density
of the east region was over three times the state average, with
73.7 people per square mile. The central and west regions of
Nebraska were sparsely populated with population densities of
11.7 and 5.2 persons per square mile, respectively. The overall
seroprevalence for WNV in Nebraska statewide of 9.5% (95%
CI, 7.2 to 11.8) suggested that possibly 161,800 individuals
(95% CI, 127,531 to 209,009) may have developed a subclinical
WNV infection during 2003.
The MIR overall for the mosquitoes tested in Nebraska was
5.8 infected per 1,000 mosquitoes tested (Table 3). The MIR
for the east region was 1.4, that for the central region was 7.7,
and that for the west region was 4.9.
DISCUSSION
Following an epidemic of confirmed WNV infections in Ne-
braska during the 2003 mosquito season, a seroprevalence study
was performed to determine the extent of individuals who devel-
TABLE 2. Estimation of the seroprevalence of West Nile virus in
Nebraska regions
Region Population
a
(%)
Population
densityb
Seroprevalence estimate
No.
positivec 95% CI
East 1,234 (69.7) 73.7 51.8 25.9–77.7
Central 305 (17.2) 11.7 42.1 24.4–59.8
West 172 (13.1) 5.1 34.0 21.9–46.2
Total 1,711 22.3 161.8 127.5–209.0
a Based on 2000 U.S. census, presented in thousands.
b Number of people per square mile.
c Calculated by multiplying the WNV-specific positive IgG rate for each region
by total population, presented in thousands.
TABLE 3. Mosquito testing for the presence of West Nile virus
RNA in regions of Nebraska
Region No. ofmosquitoesa MIR
b
East 34,554 1.4
Central 64,104 7.7
West 62,758 4.9
Total 161,416 5.8
a Includes the total number of all Culex species tested.
b MIR was calculated by dividing the number of positive mosquito pools by the
number of mosquitoes tested and expressing this as the number of positive
mosquitoes per 1,000 mosquitoes tested.
TABLE 1. Comparison of West Nile virus-positive patient sera with positive mosquito pool samples by region
Region
Patient seraa Mosquito poolsb
No.
IgG IgM
No. No. positive(%) 95% CINo. positive
(%) 95% CI
No. positive
(%) 95% CI
Eastc,e 359 15 (4.2) 2.1–6.3 2 (0.6) 0.0–1.3 725 75 (10.3) 8.1–12.6
Centralc,d 138 19 (13.8) 8.0–19.6 6 (4.3) 0.9–7.8 1,163 528 (45.4) 42.5–48.3
Westd,e 127 25 (19.7) 12.7–26.7 4 (3.2) 0.1–6.2 928 333 (35.9) 32.8–39.0
Total 624 59 (9.5) 7.2–11.8 12 (1.9) 0.8–3.0 2,816 936 (33.2) 31.5–35.0
a Patient sera were collected on 1 July 2004 from healthy blood donors.
b Mosquito pools were collected during June to October 2003. Each pool consisted of up to 50 female Culex species.
c East compared to central: IgG (P  0.001), IgM (P  0.01), and mosquito pools (P  0.001).
d Central compared to west: IgG (P  0.25), IgM (P  0.50), and mosquito pools (P  0.001).
e West compared to east: IgG (P  0.001), IgM (P  0.12), and mosquito pools (P  0.001).
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oped WNV-specific antibodies from various regions within the
state. To date, only limited seroprevalence studies have been
performed in areas of the United States as WNV moves across
the nation (13, 14). The broad expanse of Nebraska with multiple
environments and the large number of WNV cases that occurred
during 2003 provided the opportunity to study in more detail the
impact that geographic factors may have had on human sero-
prevalence rates.
Of the 624 healthy blood donor sera collected about 8 months
after the 2003 epidemic, 9.5% were positive for WNV-specific
IgG antibodies. In comparing the results for each region of the
state, the prevalence of WNV IgG antibodies was lower in donors
from the east than in those from the central or west region. In
comparison, a report from the evaluation of NYC residents fol-
lowing a 1999 outbreak in that area showed that 2.6% of the
population developed antibodies to WNV (13).
The greater-than-3.5 times increase in the percentage of
the population that had detectable WNV-specific antibodies
within Nebraska compared to NYC may be due to multiple
variables. Vector exposure and the species of mosquito vector
would be major variables to consider. Janousek and Kramer
showed that floodwater mosquitoes (Aedes sp.) were more
prevalent in the eastern areas of Nebraska, while the standing-
water mosquitoes (Culex sp.), which are more likely to transmit
WNV, were more prevalent in western portions of the state
(8). The effectiveness of virus transfer by the different species
within the genus varies, with Culex tarsalis considered one of
the most efficient vectors within the group (1, 6, 15, 22). During
the present study, C. tarsalis was the most common Culex mos-
quito detected in western Nebraska (data not shown). A major
difference in prevalence between NYC and western Nebraska
may have been the species of mosquito vector present in each
area. Culex tarsalis was not found in large numbers in NYC or in
eastern Nebraska but was the predominant species in the central
and west regions of Nebraska (8, 13, 15).
A similar serosurvey was performed on residents from Goshen
County, Wyoming (14). In this study, 14% of the population was
considered to be infected with WNV. Since this county borders
western Nebraska, a similar geography and mosquito population
were present. The CI obtained from testing in the western region
of Nebraska was 12.7 to 26.7, so it is reasonable to assume that the
14% seroprevalence rate detected in Wyoming corresponds to
the rates detected in western Nebraska as a part of the present
study (14). No mosquito data were reported from the Wyoming
project for comparison purposes.
Twelve of the 624 donor sera (1.9%) were positive for
WNV-specific IgM. These sera were also positive for WNV
IgG antibodies. In most other serological applications, the
presence of specific IgM antibodies suggests acute infection.
Previous research, however, has shown that WNV-specific IgM
can persist in humans up to 500 days after onset of symptoms
(9, 17, 18). The presence of IgM antibodies in conjunction with
WNV-specific IgG, therefore, does not necessarily indicate
acute infection. The results for the IgM-positive samples were
close to the negative cutoff, while the corresponding IgG re-
sults were well above the negative cutoff as described by the
assay procedures.
To evaluate further the significance of a WNV-specific IgM
titer, IgA antibodies were also considered as a possible pre-
dictor of acute disease (16, 17). None of the IgM-positive sera
in the present study were positive for WNV-specific IgA. These
results compared with the findings of Lanciotti, who presented
data to indicate that WNV IgA was rarely detected in serum
samples collected from WNV-infected patients 50 days after
onset (10). Prince et al., however, showed that both the WNV
IgM and IgA persisted for at least 6 months after infection
(17). They, however, suggested that IgA detection did not
appear to be a useful adjunct to WNV IgM detection to iden-
tify very recent WNV infection. The discrepancy in IgA levels
between studies may be due to multiple issues including the
study group tested and the immunological assays used, since no
commercial product is available for the testing of WNV IgA
and the methods were developed in house. More studies are
needed to determine the relevance of detecting IgM antibodies
long after the onset of acute WNV illness and the role that
WNV-specific IgA may have in the serological evaluation for
WNV disease.
The ELISA-based test utilized in the present study does not
differentiate between infections caused by WNV and those
caused by SLEV, and further testing of positive samples was
done to confirm the presence of WNV-specific antibodies.
HAI testing of all IgG-positive samples verified the presence
of WNV-specific neutralizing antibodies. This was not unex-
pected, since SLEV infection cases have rarely been reported
as a cause of human disease in Nebraska (7).
Mosquito surveillance for the presence of arboviruses has
been done in most states, and the results of testing have been
made electronically available as a means to predict WNV ac-
tivity for control of disease outbreaks (http://westnilemaps.usgs
.gov). Testing results have shown that the MIR necessary to
cause outbreaks of human disease varies among mosquito
species (6). In the present study, the MIRs of WNV-infected
mosquitoes ranged from 1.4 to 7.7 among the three regions of
Nebraska. This correlates with what had been seen during
previous years of the WNV outbreak in other states, where the
MIR ranged from 0.07 to 5.7 (6). The prevalence of WNV-
positive mosquitoes was significantly higher in the central re-
gion of Nebraska than in either the west or east area, corre-
lating with the higher WNV antibody rates.
An observation of note concerning WNV seroprevalence
was that the rate was higher in the west than in the central
region, while mosquito WNV-positive rates were higher in the
central than in the west region. One explanation for the dis-
crepancy was the high number of infected mosquitoes collected
in Dawson County (accounting for 49.2% of the total positive
mosquito pools from the central region), a county which is
adjacent to the western region (Fig. 1). The prevalence of
WNV-positive mosquitoes in this county was reflective of the
prevalence rate for the west region, illustrating one of the
limitations to conducting this type of comparative analysis.
This county has geological and environmental aspects similar
to those of counties to the west, which may account for simi-
larities in the number of positive mosquitoes detected.
The population density in NYC was 26,403 people per square
mile compared to 73.7, 11.7, and 5.1 people per square mile in the
east, central, and west regions of Nebraska, respectively. Addi-
tionally, the MIR of mosquitoes in NYC ranged from 0.7 to 57.1
while similar surveillance in Nebraska found the MIRs to range
from 1.4 to 7.7. The presence of an efficient vector, even in an
area with a low population density, appears to put people at a
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higher risk of infection. These results show that population den-
sity does not always correlate with higher risk, but other factors
such as mosquito species and exposure to these vectors need to be
considered. No other studies to our knowledge have evaluated
population density and similar MIRs in comparison with mos-
quito species and human WNV seroprevalence rates.
In consideration of the number of individuals who were
identified as positive for WNV-specific IgG and comparing this
with the total state population, it seems highly possible that the
number of individuals in Nebraska who may have developed a
silent infection with WNV may be large (ranging from 127,500
to 209,000 individuals). Since the risk of exposure to infected
mosquitoes appeared to be less in the east, where the popula-
tion density was greatest, the detection of WNV-specific anti-
bodies in humans could have theoretically been higher if the
population density of the east were present in the western
region of the state. Additional studies are needed to further
evaluate population densities and the risk of WNV exposure.
This study was conducted to determine the seroprevalence
of WNV antibodies in the human population following an
epidemic. The results showed that a high percentage of indi-
viduals may have developed subclinical infections leading to
the production of WNV-specific antibodies. This evaluation
also confirmed, as expected, that regions of the state with high
mosquito WNV infectivity have a higher risk of individuals
developing WNV infections, even in areas where the popula-
tion density is low. Additional studies are needed to determine
what effects high WNV seroprevalence may have on the future
incidence of WNV-caused infections and what impact environ-
mental and geographical factors may have on outbreaks of
disease.
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